Invex Therapeutics (ASX:IVX)
Invex has received an approval from the UK’s MHRA to commence its IIH EVOLVE Phase III clinical trial in the country. The trial will study patients with Idiopathic Intracranial Hypertension (IIH), and they will be randomly treated with Presendin versus placebo once weekly over 24 weeks.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.541M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.9¢ | 10 | 1 |
View Market Depth
| Last trade - 08.08am 31/07/2025 (20 minute delay) ? |
| IVX (ASX) Chart |
Day chart unavailable